The roles and therapeutic potentials of Ephs and ephrins in lung cancer

Experimental Cell Research

Volumn 319, Issue 2, 2013, Pages 152-159

  Li, Jing Jing ^a   Xie, Dong ^a  

^a Shanghai Jiao Tong University Affiliated Sixth People s Hospital   (China)

Author keywords

Eph; Ephrin; Lung cancer

Indexed keywords

DASATINIB; EPHRIN; EPHRIN A1; EPHRIN RECEPTOR; EPHRIN RECEPTOR A1; EPHRIN RECEPTOR A2; EPHRIN RECEPTOR A3; EPHRIN RECEPTOR A4; EPHRIN RECEPTOR A5; EPHRIN RECEPTOR B1; EPHRIN RECEPTOR B2; EPHRIN RECEPTOR B3; FAS LIGAND; K RAS PROTEIN; PHOSPHOPROTEIN PHOSPHATASE 2A; S6 KINASE; TYROSINE KINASE RECEPTOR; VASCULOTROPIN RECEPTOR;

ANGIOGENESIS; CANCER PROGNOSIS; CELL GROWTH; CELL SURVIVAL; CHRONIC MYELOID LEUKEMIA; GENE MUTATION; HUMAN; LARGE CELL CARCINOMA; LUNG CANCER; LUNG CARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; METASTASIS; MOLECULARLY TARGETED THERAPY; NONHUMAN; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVIEW; SQUAMOUS CELL CARCINOMA; TUMOR MICROENVIRONMENT;

EID: 84870737113     PISSN: 00144827     EISSN: 10902422     Source Type: Journal    
DOI: 10.1016/j.yexcr.2012.08.005     Document Type: Review

References (51)

1. Ferlay J., Shin H.R., Bray F., Forman D., Mathers C., Parkin D.M. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int. J. Cancer 2010, 127:2893-2917.
2. Yamagata N., Shyr Y., Yanagisawa K., Edgerton M., Dang T.P., Gonzalez A., Nadaf S., Larsen P., Roberts J.R., Nesbitt J.C., Jensen R., Levy S., Moore J.H., Minna J.D., Carbone D.P. A training-testing approach to the molecular classification of resected non-small cell lung cancer. Clin. Cancer Res. 2003, 9:4695-4704.
3. National Cancer Institute SEER stat fact sheets: lung and bronchuw, accessed September 8, 2012. http://seer.cancer.gov/statfacts/html/lungb.html.
4. Brantley-Sieders D., Schmidt S., Parker M., Chen J. Eph receptor tyrosine kinases in tumor and tumor microenvironment. Curr. Pharm. Des. 2004, 10:3431-3442.
5. Flanagan J.G., Vanderhaeghen P. The ephrins and Eph receptors in neural development. Annu. Rev. Neurosci. 1998, 21:309-345.
6. Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., Davies H., Teague J., Butler A., Edkins S., O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.E., Defazio A., Greaves M.F., Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., Tan M.H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R. Patterns of somatic mutation in human cancer genomes. Nature 2007, 446:153-158.
7. Davies H., Hunter C., Smith R., Stephens P., Greenman C., Bignell G., Teague B., Butler A., Edkins S., Stevens C., Parker A., O'Meara S., Avis T., Barthorpe S., Brackenbury L., Buck G., Clements B., Cole J., Dicks E., Edwards K., Forbes S., Gorton M., Gray K., Halliday K., Harrison R., Hills K., Hinton J., Jones D., Kosmidou V., Laman R., Lugg R., Menzies A., Perry J., Petty R., Raine K., Shepherd R., Small A., Solomon H., Stephens Y., Tofts C., Varian J., Webb A., West S., Widaa S., Yates A., Brasseur F., Cooper C.S., Flanagan A.M., Green A., Knowles M., Leung S.Y., Looijenga L.H.J., Malkowicz B., Pierotti M.A., Teh B.T., Yuen S.T., Lakhani S.R., Easton D.F., Weber B.L., Goldstraw P., Nicholson A.G., Wooster R., Stratton M.R., Futreal P.A. Somatic mutations of the protein kinase gene family in human lung cancer. Cancer Res. 2005, 65:7591-7595.
8. Ding L., Getz G., Wheeler D.A., Mardis E.R., McLellan M.D., Cibulskis K., Sougnez C., Greulich H., Muzny D.M., Morgan M.B., Fulton L., Fulton R.S., Zhang Q., Wendl M.C., Lawrence M.S., Larson D.E., Chen K., Dooling D.J., Sabo A., Hawes A.C., Shen H., Jhangiani S.N., Lewis L.R., Hall O., Zhu Y., Mathew T., Ren Y., Yao J., Scherer S.E., Clerc K., Metcalf G.A., Ng B., Milosavljevic A., Gonzalez-Garay M.L., Osborne J.R., Meyer R., Shi X., Tang Y., Koboldt D.C., Lin L., Abbott R., Miner T.L., Pohl C., Fewell G., Haipek C., Schmidt H., Dunford-Shore B.H., Kraja A., Crosby S.D., Sawyer C.S., Vickery T., Sander S., Robinson J., Winckler W., Baldwin J., Chirieac L.R., Dutt A., Fennell T., Hanna M., Johnson B.E., Onofrio R.C., Thomas R.K., Tonon G., Weir B.A., Zhao X., Ziaugra L., Zody M.C., Giordano T., Orringer M.B., Roth J.A., Spitz M.R., Wistuba I.I., Ozenberger B., Good P.J., Chang A.C., Beer D.G., Watson M.A., Ladanyi M., Broderick S., Yoshizawa A., Travis W.D., Pao W., Province M.A., Weinstock G.M., Varmus H.E., Gabriel S.B., Lander E.S., Gibbs R.A., Meyerson M., Wilson R.K. Somatic mutations affect key pathways in lung adenocarcinoma. Nature 2008, 455:1069-1075.
9. Wood L.D., Calhoun E.S., Silliman N., Ptak J., Szabo S., Powell S.M., Riggins G.J., Wang T.-L., Yan H., Gazdar A., Kern S.E., Pennacchio L., Kinzler K.W., Vogelstein B., Velculescu V.E. Somatic mutations of GUCY2F, EPHA3, and NTRK3 in human cancers. Hum. Mutat. 2006, 27:1060-1061.
10. Lisabeth E.M., Fernandez C., Pasquale E.B. Cancer somatic mutations disrupt functions of the EphA3 receptor tyrosine kinase through multiple mechanisms. Biochemistry 2012, 51:1464-1475.
11. Faoro L., Singleton P.A., Cervantes G.M., Lennon F.E., Choong N.W., Kanteti R., Ferguson B.D., Husain A.N., Tretiakova M.S., Ramnath N., Vokes E.E., Salgia R. EphA2 mutation in lung squamous cell carcinoma promotes increased cell survival, cell invasion, focal adhesions, and mammalian target of rapamycin activation. J. Biol. Chem. 2010, 285:18575-18585.
12. Kinch M.S., Moore M.B., Harpole D.H. Predictive value of the EphA2 receptor tyrosine kinase in lung cancer recurrence and survival. Clin. Cancer Res. 2003, 9:613-618.
13. Brannan J.M., Sen B., Saigal B., Prudkin L., Behrens C., Solis L., Dong W., Bekele B.N., Wistuba I., Johnson F.M. EphA2 in the early pathogenesis and progression of non-small cell lung cancer. Cancer Prev. Res. 2009, 2:1039-1049.
14. Brannan J.M., Dong W., Prudkin L., Behrens C., Lotan R., Bekele B.N., Wistuba I., Johnson F.M. Expression of the receptor tyrosine kinase EphA2 is increased in smokers and predicts poor survival in non-small cell lung cancer. Clin. Cancer Res. 2009, 15:4423-4430.
15. Macrae M., Neve R.M., Rodriguez-Viciana P., Haqq C., Yeh J., Chen C.R., Gray J.W., McCormick F. A conditional feedback loop regulates Ras activity through EphA2. Cancer Cell 2005, 8:111-118.
16. Larsen A.B., Pedersen M.W., Stockhausen M.-T., Grandal M.V., van Deurs B., Poulsen H.S. Activation of the EGFR gene target EphA2 inhibits epidermal growth factor-induced cancer cell motility. Mol. Cancer Res. 2007, 5:283-293.
17. Yu J., Bulk E., Ji P., Hascher A., Tang M., Metzger R., Marra A., Serve H., Berdel W.E., Wiewroth R., Koschmieder S., Mueller-Tidow C. The EPHB6 receptor tyrosine kinase is a metastasis suppressor that is frequently silenced by promoter DNA Hypermethylation in non-small cell lung cancer. Clin. Cancer Res. 2010, 16:2275-2283.
18. Kullander K., Klein R. Mechanisms and functions of EPH and ephrin signalling. Nat. Rev. Mol. Cell Biol. 2002, 3:475-486.
19. Nasreen N., Mohammed K.A., Lai Y., Antony V.B. Receptor EphA2 activation with ephrinA1 suppresses growth of malignant mesothelioma (MM). Cancer Lett. 2007, 258:215-222.
20. Lee H.-Y., Mohammed K.A., Peruvemba S., Goldberg E.P., Nasreen N. Targeted lung cancer therapy using ephrinA1-loaded albumin microspheres. J. Pharm. Pharmacol. 2011, 63:1401-1410.
21. Ji X.-D., Li G., Feng Y.-X., Zhao J.-S., Li J.-J., Sun Z.-J., Shi S., Deng Y.-Z., Xu J.-F., Zhu Y.-Q., Koeffler H.P., Tong X.-J., Xie D. EphB3 is overexpressed in non-small-cell lung cancer and promotes tumor metastasis by enhancing cell survival and migration. Cancer Res. 2011, 71:1156-1166.
22. Stahl S., Branca R.M., Efazat G., Ruzzene M., Zhivotovsky B., Lewensohn R., Viktorsson K., Lehtio J. Phosphoproteomic profiling of NSCLC cells reveals that Ephrin B3 regulates pro-survival signaling through Akt1-mediated phosphorylation of the EphA2 receptor. J. Proteome Res. 2011, 10:2566-2578.
23. Polte T.R., Hanks S.K. Complexes of focal adhesion kinase (FAK) and Crk-associated substrate (p130(Cas)) are elevated in cytoskeleton-associated fractions following adhesion and Src transformation-requirements for Src kinase activity and FAK proline-rich motifs. J. Biol. Chem. 1997, 272:5501-5509.
24. Carter N., Nakamoto T., Hirai H., Hunter T. EphrinA1-induced cytoskeletal re-organization requires FAK and p130(cas). Nat. Cell Biol. 2002, 4:565-573.
25. Li G., Ji X.-D., Gao H., Zhao J.-S., Xu J.-F., Sun Z.-J., Deng Y.-Z., Shi S., Feng Y.-X., Zhu Y.-Q., Wang T., Li J.-J., Xie D. EphB3 suppresses non-small-cell lung cancer metastasis via a PP2A/RACK1/Akt signalling complex. Nat. Commun. 2012, 3.
26. Kumar S.R., Singh J., Xia G.B., Krasnoperov V., Hassanieh L., Ley E.J., Scehnet J., Kumar N.G., Hawes D., Press M.F., Weaver F.A., Gill P.S. Receptor tyrosine kinase EphB4 is a survival factor in breast cancer. Am. J. Pathol. 2006, 169:279-293.
27. Noren N.K., Foos G., Hauser C.A., Pasquale E.B. The EphB4 receptor suppresses breast cancer cell tumorigenicity through an Abl-Crk pathway. Nat. Cell Biol. 2006, 8:815-U853.
28. Miao H., Li D.-Q., Mukherjee A., Guo H., Petty A., Cutter J., Basilion J.P., Sedor J., Wu J., Danielpour D., Sloan A.E., Cohen M.L., Wang B. EphA2 mediates ligand-dependent inhibition and ligand-independent promotion of cell migration and invasion via a reciprocal regulatory loop with Akt. Cancer Cell 2009, 16:9-20.
29. Yu J., Bulk E., Ji P., Hascher A., Koschmieder S., Berdel W.E., Mueller-Tidow C. The kinase defective EPHB6 receptor tyrosine kinase activates MAP kinase signaling in lung adenocarcinoma. Int. J. Oncol. 2009, 35:175-179.
30. Mueller-Tidow C., Diederichs S., Bulk E., Pohle T., Steffen B., Schwaeble J., Plewka S., Thomas M., Metzger R., Schneider P.M., Brandts C.H., Berdel W.E., Serve H. Identification of metastasis-associated receptor tyrosine kinases in non-small cell lung cancer. Cancer Res. 2005, 65:1778-1782.
31. Cheng N., Brantley D.M., Chen J. The ephrins and Eph receptors in angiogenesis. Cytokine Growth Factor Rev. 2002, 13:75-85.
32. Favre C.J., Mancuso M., Maas K., McLean J.W., Baluk P., McDonald D.M. Expression of genes involved in vascular development and angiogenesis in endothelial cells of adult lung. Am. J. Physiol.-Heart Circ. Physiol. 2003, 285:H1917-H1938.
33. Yamanda S., Ebihara S., Asada M., Okazaki T., Niu K., Ebihara T., Koyanagi A., Yamaguchi N., Yagita H., Arai H. Role of ephrinB2 in nonproductive angiogenesis induced by delta-like 4 blockade. Blood 2009, 113:3631-3639.
34. Fromigue O., Louis K., Dayem M., Milanini J., Pages G., Tartare-Deckert S., Ponzio G., Hofman P., Barbry P., Auberger P., Mari B. Gene expression profiling of normal human pulmonary fibroblasts following coculture with non-small-cell lung cancer cells reveals alterations related to matrix degradation, angiogenesis, cell growth and survival. Oncogene 2003, 22:8487-8497.
35. Wang B. Cancer cells exploit the Eph-Ephrin system to promote invasion and metastasis: tales of unwitting partners. Sci. Signaling 2011, 4:28.
36. Bremnes R.M., Al-Shibli K., Donnem T., Sirera R., Al-Saad S., Andersen S., Stenvold H., Camps C., Busund L.-T. The role of tumor-infiltrating immune cells and chronic inflammation at the tumor site on cancer development, progression, and prognosis emphasis on non-small cell lung cancer. J. Thorac. Oncol. 2011, 6:824-833.
37. Wu J., Luo H. Recent advances on T-cell regulation by receptor tyrosine kinases. Curr. Opin. Hematol. 2005, 12:292-297.
38. Ivanov A.I., Romanovsky A.A. Putative dual role of ephrin-Eph receptor interactions in inflammation. IUBMB Life 2006, 58:389-394.
39. Huang F., Reeves K., Han X., Fairchild C., Platero S., Wong T.W., Lee F., Shaw P., Clark E. Identification of candidate molecular markers predicting sensitivity in solid tumors to dasatinib: rationale for patient selection. Cancer Res. 2007, 67:2226-2238.
40. Chang Q., Jorgensen C., Pawson T., Hedley D.W. Effects of dasatinib on EphA2 receptor tyrosine kinase activity and downstream signalling in pancreatic cancer. B. J. Cancer 2008, 99:1074-1082.
41. Li J., Rix U., Fang B., Bai Y., Edwards A., Colinge J., Bennett K.L., Gao J., Song L., Eschrich S., Superti-Furga G., Koomen J., Haura E.B. A chemical and phosphoproteomic characterization of dasatinib action in lung cancer. Nat. Chem. Biol. 2010, 6:291-299.
42. Johnson F.M., Bekele B.N., Feng L., Wistuba I., Tang X.M., Tran H.T., Erasmus J.J., Hwang L.-L., Takebe N., Blumenschein G.R., Lippman S.M., Stewart D.J. Phase II study of Dasatinib in patients with advanced non-small-cell lung cancer. J. Clin. Oncol. 2010, 28:4609-4615.
43. Noberini R., Koolpe M., Peddibhotla S., Dahl R., Su Y., Cosford N.D.P., Roth G.P., Pasquale E.B. Small molecules can selectively inhibit ephrin binding to the EphA4 and EphA2 receptors. J. Biol. Chem. 2008, 283:29461-29472.
44. Koolpe M., Burgess R., Dail M., Pasquale E.B. EphB receptor-binding peptides identified by phage display enable design of an antagonist with ephrin-like affinity. J. Biol. Chem. 2005, 280:17301-17311.
45. Noberini R., Koolpe M., Lamberto I., Pasquale E.B. Inhibition of Eph receptor-ephrin ligand interaction by tea polyphenols. Pharmacol. Res. 2012, Jun 28, [Epub ahead of print].
46. Lamberto I., Qin H., Noberini R., Premkumar L., Bourgin C., Riedl S.J., Song J., Pasquale E.B. Distinctive binding of three antagonistic peptides to the ephrin-binding pocket of the EphA4 receptor. Biochem. J. 2012, 445:47-56.
47. Lee J.-W., Stone R.L., Lee S.J., Nam E.J., Roh J.-W., Nick A.M., Han H.-D., Shahzad M.M.K., Kim H.-S., Mangala L.S., Jennings N.B., Mao S., Gooya J., Jackson D., Coleman R.L., Sood A.K. EphA2 targeted chemotherapy using an antibody drug conjugate in endometrial carcinoma. Clin. Cancer Res. 2010, 16:2562-2570.
48. Landen C.N., Lu C., Han L.Y., Coffman K.T., Bruckheimer E., Halder J., Mangala L.S., Merritt W.M., Lin Y.G., Gao C., Schmandt R., Kamat A.A., Li Y., Thaker P., Gershenson D.M., Parikh N.U., Gallick G.E., Kinch M.S., Sood A.K. Efficacy and antivascular effects of EphA2 reduction with an agonistic antibody in ovarian cancer. J. Natl. Cancer Inst. 2006, 98:1558-1570.
49. Gobin A.M., Moon J.J., West J.L. EphrinA1-targeted nanoshells for photothermal ablation of prostate cancer cells. Int. J. Nanomed. 2008, 3:351-358.
50. Hafner C., Schmitz G., Meyer S., Bataille F., Hau P., Langmann T., Dietmaier W., Landthaler M., Vogt T. Differential gene expression of Eph receptors and ephrins in benign human tissues and cancer. Clin. Chem. 2004, 50:490-499.
51. Lugli A., Spichtin H., Maurer R., Mirlacher M., Kiefer J., Huusko P., Azorsa D., Terracciano L., Sauter G., Kallioniemi O.P., Mousses S., Tornillo.L. EphB2 expression across 138 human tumor types in a tissue microarray: high levels of expression in gastrointestinal cancers. Clin. Cancer Res. 2005, 11:6450-6458.